Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
NZ778138B2 - Therapeutic binding compounds - Google Patents
[go: Go Back, main page]

NZ778138B2 - Therapeutic binding compounds - Google Patents

Therapeutic binding compounds

Info

Publication number
NZ778138B2
NZ778138B2 NZ778138A NZ77813817A NZ778138B2 NZ 778138 B2 NZ778138 B2 NZ 778138B2 NZ 778138 A NZ778138 A NZ 778138A NZ 77813817 A NZ77813817 A NZ 77813817A NZ 778138 B2 NZ778138 B2 NZ 778138B2
Authority
NZ
New Zealand
Prior art keywords
sequence
yfdywgqgilvtvss
heavy chain
yfhywgqgilvtvss
binding compounds
Prior art date
Application number
NZ778138A
Other versions
NZ778138A (en
Inventor
Christien Fatmawati
Daniel Michiel Go
Wouter Pos
Remko Schotte
Hergen Spits
Helden Paula Maria Wilhelmina Van
Julien Christian Villaudy
Koen Wagner
Original Assignee
Kling Biotherapeutics Bv
Filing date
Publication date
Application filed by Kling Biotherapeutics Bv filed Critical Kling Biotherapeutics Bv
Publication of NZ778138A publication Critical patent/NZ778138A/en
Publication of NZ778138B2 publication Critical patent/NZ778138B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G01N33/57492—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Abstract

The present invention provides novel binding compounds and therapeutic applications thereof.

Claims (2)

Claims
1. A chimeric antigen receptor (CAR) T cell that comprises: - a heavy chain CDR1 sequence DYAMH or DYAMY; and 5 - a heavy chain CDR2 sequence GISWNSGSIVYADSVKG; and - a heavy chain CDR3 sequence AVSGYYPYFDY or AVSGYFPYFDY or AVSGYYPYFHY or AVSGYFPYFHY, and - a light chain CDR1 sequence KSSQSVLYSSNNKNYLG; and - a light chain CDR2 sequence WASTRES or WASIRES; and 10 - a light chain CDR3 sequence QQYYTTP.
2. A CAR T cell according to claim 1, that comprises: - a heavy chain variable region sequence EVQVVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGIS 15 WNSGSIVYADSVKGRFTISRDNAKNSLYLQLNSLRAEDTAFYYCAKAVSGYYP YFDYWGQGILVTVSS, or EVQVVESGGGLVQPGRSLRLSCAASGFTFDDYAMYWVRQAPGKGLEWVSGIS WNSGSIVYADSVKGRFTISRDNAKNSLYLQLNSLRAEDTAFYYCAKAVSGYFP YFDYWGQGILVTVSS, or 20 EVQVVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGIS WNSGSIVYADSVKGRFTISRDNAKNSLYLQLNSLRAEDTAFYYCAKAVSGYFP YFDYWGQGILVTVSS, or EVQVVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGIS WNSGSIVYADSVKGRFTISRDNAKNSLYLQLNSLRAEDTAFYYCAKAVSGYFP 25 YFHYWGQGILVTVSS, or EVQVVESGGGLVQPGRSLRLSCAASGFTFDDYAMYWVRQAPGKGLEWVSGIS WNSGSIVYADSVKGRFTISRDNAKNSLYLQLNSLRAEDTAFYYCAKAVSGYFP YFHYWGQGILVTVSS, or EVQVVESGGGLVQPGRSLRLSCAASGFNFDDYAMYWVRQAPGKGLEWVSGIS 30 WNSGSIVYADSVKGRFTISRDNAKNSLYLQLNSLRAEDTAFYYCAKAVSGYFP YFHYWGQGILVTVSS, or EVQVVESGGGLVQPGRSLRLSCAASGFTFDDYAMYWVRQAPGKGLEWVSGIS WNSGSIVYADSVKGRFTISRDNAKNSLYLQLNSLRAEDTAFYYCAKAVSGYYP YFDYWGQGILVTVSS, or
NZ778138A 2017-01-06 Therapeutic binding compounds NZ778138B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16150698 2016-01-08
NZ744187A NZ744187B2 (en) 2016-01-08 2017-01-06 Therapeutic anti-cd9 antibody

Publications (2)

Publication Number Publication Date
NZ778138A NZ778138A (en) 2025-08-29
NZ778138B2 true NZ778138B2 (en) 2025-12-02

Family

ID=

Similar Documents

Publication Publication Date Title
MY200988A (en) CD3 Binding Antibodies
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
EP4286415A3 (en) Humanized antigen-binding domains against cd19 and methods of use
HK1257518A1 (en) Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
PH12019501464A1 (en) Novel anti-human transferrin receptor antibody capable of penetrating blood-brain barrier
NZ630610A (en) Tau peptides, anti-tau antibodies, and methods of use thereof
MY190771A (en) Anti-pd-l1 antibodies and uses thereof
AU2018282038A1 (en) Anti TRBC1 antigen binding domains
NZ601617A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
JP2019528240A5 (en)
WO2016180782A8 (en) Claudin-18.2-specific immunoreceptors and t cell epitopes
PE20190737A1 (en) ANTI-CD27 ANTIBODIES
NZ602294A (en) Monoclonal antibodies against c-met
WO2015127136A3 (en) Ebola monoclonal antibodies
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
IL278244A (en) Antibodies, and bispecific antigen-binding molecules that bind her2 and/or aplp2, conjugates, and uses thereof
PH12017500699A1 (en) Antibodies that bind to ccr6 and their uses
EP4049684A4 (en) Ri-labeled humanized antibody
WO2018217918A3 (en) Therapeutic anti-cd40 ligand antibodies
WO2017021539A3 (en) Novel anti-human gpvi antibodies and uses thereof
WO2015091935A3 (en) Antibodies directed against the lukgh (lukab) toxin of staphylococcus aureus and antibody sequences
NZ631473A (en) Anti-cd52 antibodies
AU2017255888A1 (en) Humanized anti-BASIGIN antibodies and the use thereof
WO2020206149A3 (en) Methods and compositions involving chimeric binding polypeptides